Pharmaron Beijing Co Ltd
SZSE:300759

Watchlist Manager
Pharmaron Beijing Co Ltd Logo
Pharmaron Beijing Co Ltd
SZSE:300759
Watchlist
Price: 29.62 CNY -2.69% Market Closed
Market Cap: ¥52.5B

Pharmaron Beijing Co Ltd
Short-Term Debt

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Pharmaron Beijing Co Ltd
Short-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Short-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Pharmaron Beijing Co Ltd
SZSE:300759
Short-Term Debt
¥1.3B
CAGR 3-Years
24%
CAGR 5-Years
27%
CAGR 10-Years
N/A
J
Joinn Laboratories China Co Ltd
SSE:603127
Short-Term Debt
¥0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Short-Term Debt
¥6B
CAGR 3-Years
15%
CAGR 5-Years
37%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Short-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Short-Term Debt
¥550.2m
CAGR 3-Years
-34%
CAGR 5-Years
92%
CAGR 10-Years
8%
W
WuXi XDC Cayman Inc
HKEX:2268
Short-Term Debt
¥842m
CAGR 3-Years
128%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Pharmaron Beijing Co Ltd
Glance View

Pharmaron Beijing Co Ltd., a dynamic player in the biotech and pharmaceutical services sector, has carved a niche by capitalizing on the demand for comprehensive R&D services. Founded in 2004, the company emerged at a time when global pharmaceutical companies were grappling with skyrocketing research costs and the increasing complexity of drug development. Pharmaron offers a broad spectrum of services across the drug discovery and development pipeline, including laboratory services, chemistry, biology, and pharmacology, effectively monetizing its expertise by partnering with global pharmaceutical firms. By providing integrated solutions that cover the entire span of research, from preclinical development to commercial manufacturing, Pharmaron positions itself as an indispensable ally for companies aiming to streamline their product development journeys. The company’s revenue model thrives on long-term partnerships and collaborations with some of the industry's leading pharmaceutical and biotech firms. Using a client-centric approach, Pharmaron aligns its capabilities with customer needs, ensuring scalable and customizable service offerings. This close alignment not only enhances client satisfaction but also encourages repeat business, fostering a cycle of sustainable revenue growth. In recent years, Pharmaron has been expanding its geographical footprint and service capacity through strategic acquisitions and investments in state-of-the-art facilities and technologies, aiming to bolster its position in key markets across the US, Europe, and China. As the pharmaceutical landscape continues to evolve, Pharmaron leverages its robust R&D service portfolio and strategic alliances to maintain its growth trajectory amidst a backdrop of increasing globalization and technological advancement in the industry.

Intrinsic Value
34.82 CNY
Undervaluation 15%
Intrinsic Value
Price ¥29.62

See Also

What is Pharmaron Beijing Co Ltd's Short-Term Debt?
Short-Term Debt
1.3B CNY

Based on the financial report for Dec 31, 2025, Pharmaron Beijing Co Ltd's Short-Term Debt amounts to 1.3B CNY.

What is Pharmaron Beijing Co Ltd's Short-Term Debt growth rate?
Short-Term Debt CAGR 5Y
27%

Over the last year, the Short-Term Debt growth was 65%. The average annual Short-Term Debt growth rates for Pharmaron Beijing Co Ltd have been 24% over the past three years , 27% over the past five years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett